cardio-met Profile picture
Apr 5 36 tweets 26 min read
9) Many risk factors modulate the propensity of LDL-C to traverse the endothelium and enter the arterial intima. See 🔓academic.oup.com/eurheartj/arti….
10) It now appears that the passage of #LDL into the #intima is not a merely passive process whereby the concentration in blood & the permeability of the endothelium determine LDL accumulation.
11) It’s #Transcytosis (an active process), through a vesicular pathway involving #caveolae, scavenger receptors (#SRB1) and activin like receptor kinase 1 (#ALK1). Hence for a given blood level of LDL-C the amount of atherosclerosis is variable.
12) Both quality and quality of the apoB containing lipoproteins can contribute to the clinical #ASCVD phenotype. Again, see 🔓academic.oup.com/eurheartj/arti….
13) Cell-specific responses to retained and modified #LDL include a sterile inflammatory response through expression of adhesion molecules and attracting monocytes which differentiate into #macrophages.
14) Retained #LDL particles are taken up by macrophages resulting in #foamcell formation. Lipid retention in macrophages can lead to #NLRP #inflammasome activation. 🔓academic.oup.com/eurheartj/arti…
15) Large-scale genetic studies show that #CV outcomes not only depend upon duration of exposure to #LDL-C, but are agnostic to the method by which it is achieved. A unit difference in LDL-C achieved . . .
16) . . . through genetic variations in pathways that mimic #statins (#HMGCoA), #ezetimibe (#NCP1L1), #PCSK9 (monoclonals or #inclisiran), ACLY (bempedoic acid), results in similar differences in risk of #CHD. See 🔓nejm.org/doi/full/10.10…
17) Similarly in #RCTs of statins and #PCSK9i when #LDL-C differences are standardized per unit change and duration of treatment, similar relative risk reductions are observed.
18) This suggests that although statins are associated with changes in inflammatory markers as well as #LDL-C, and #PCSK9i with reductions in LDL-C and Lp(a), virtually all of the clinical benefit of these treatments at a population level are explained by changes in LDL-C.
19) So, a quick knowledge ✔️--were you paying attention? The process by which LDL-C enters arterial intima is known as:
20) Mark your response and return TOMORROW for more education on the inescapable links between #LDL-C & #atherosclerosis! Shout-outs to @GoggleDocs @Drlipid @SABOURETCardio @DrMarthaGulati @pnatarajanmd @mmamas1973 @DLBHATTMD @maciejbanach @drpablocorral @pabeda1 @TomPMarshall
Apparently some feeds are inconsistently showing tweets 5-8 of this 🧵. They are repeated here, with apologies & concern!
5) LDL cholesterol (LDL-C) is not only causal but a cumulative risk factor for ASCVD, meaning the same difference in LDL-C if maintained for a longer period of time produces greater relative benefits.
6) LDL-C fulfills the Bradford Hill Criteria for #causality, namely biological plausibility, biological gradient, strength of association, temporal relationship, specificity for ASCVD, consistency of the totality of data, external & internal validity & 🔑: reversibility.
7) Individuals have differential retention of apoB-containing lipoproteins & hence differential vulnerability to the effects of LDL-C exposure, such that most cardiovascular events occur among individuals without extreme elevations in LDL-C.
8) Apo-B containing lipoproteins up to 70 nm in diameter can cross the endothelium. As LDL is the most abundant lipoprotein in the circulation it is the key deliverer of cholesterol to the artery wall.
21b) Yesterday's quiz? Scroll back up to tweet 19 and answer if you didn't already. It's TRANSCYTOSIS--an active process by which #LDL-C enters the intima.
22) So, to the primary prevention setting. Alas, data from #WOSCOPS suggest that for those with LDL-C > 190mg/dl, risk calculators underestimate 10 year risk!
23) For instance 2/3 of patients with LDL-C > 190mg/dl would be predicted to have 10y risk below 7.5% and thus not offered statins. Yet their observed risk was twice that. This group derived greater absolute benefits.
24) In the same study long-term extension data from #WOSCOPS, over a further 15 years beyond the initial 5, suggested greater relative benefits over time (cumulative exposure), accruing, reducing #CHD deaths, #CV deaths and all-cause #mortality.
25) Clinical trials of LDL-C lowering have been harmonised using individual participant data on about 200,000 participants per 1mmol/L or 38mg/dl show that LDL-C lowering with statins . . .
26) . . ⬇️risk in relative terms similarly in those, w/ & w/o CVD, w/ & w/o risk factors but absolute benefit per unit change depends upon baseline risk, with those at greatest risk of MACE deriving greater absolute benefits. See 🔓thelancet.com/journals/lance…
pubmed.ncbi.nlm.nih.gov/18191683/
27) As increasingly guidelines recommend lower cholesterol targets for those at highest risk, this inevitably will require greater use of combination therapies.
28) For patients requiring > 50% LDL-C lowering to get to goal, or unable to tolerate statin regimens which could provide 50% lowering, due consideration to combination should occur early. 🔓pubmed.ncbi.nlm.nih.gov/31504418/
29) Combination therapies such as statins + #ezetimibe should be the norm for those patients at highest risk for whom lower LDL-C goals are recommended, thereby reducing unnecessary steps and clinical inertia.
30) If more add-on therapy is needed, options include a third oral agent such as #bempedoic acid, or injectable therapies directed against #PCSK9.
31) For those who are statin intolerant, combination therapy with statins, bempedoic acid, & ezetimibe should be first line oral options, with the addition of injectable therapies as needed. pubmed.ncbi.nlm.nih.gov/34636884/
32) Time can be your friend: by starting #LDL-C lowering early, to derive greater cumulative benefits. Benefits from small reductions started early=large reductions required later.
33) Achieve the LDL-C that is right for your patient, i.e. match degree of LDL-C lowering to risk.
34) Those who have highest risk should achieve lower LDL-C levels to mitigate that risk. Combination therapies are likely needed when aiming for lower LDL-C. Several synergistic combinations are available both as oral therapies and injectable agents.
35) For those at highest RISK , get LDL-C low and keep it low!
36) So, one last knowledge✔️. Were you keeping up? Early consideration of #combination lipid-lowering therapy #LLT should be initiated when statin monotherapy does not ➡️what % desired #LDL-C lowering?
37) Did you answer before scrolling here? As per Tweet 28, for patients requiring > 50% LDL-C lowering to get to goal, or unable to tolerate statin regimens which could provide 50% lowering, due consideration to combination should occur early. Now go forth and treat!
38) And that's it! You made it! I am @ProfKausikRay and I hope you learned useful info that will impact your practice. Now you can grab 0.5h CE/#CME for 🆓at cardiometabolic-ce.com/lipids4/. Please FOLLOW US for more education from the #cardiometabolic experts!

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with cardio-met

cardio-met Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @cardiomet_CE

Apr 5
1) Welcome to an #accredited #tweetorial on the role of ⬆️ #LDL-C levels in the pathogenesis & pathophysiology of #ASCVD. I am Kausik Ray MD FRCP @profkausikray, Professor of Public Health & Cardiologist @imperialcollege London AND President of European Atherosclerosis Society
2) This #tweetorial, accredited for #CME/CE and intended for #physicians #physicianassociates #nurses #nursepractitioners #pharmacists is supported by an educational grant from Esperion Therapeutics. See faculty disclosures at cardiometabolic-ce.com/disclosures/.
3) #Atherosclerosis starts in childhood, progresses in fits and spurts and presents in middle to late life in the form of major adverse cardiovascular events #MACE.
Read 4 tweets
Mar 29
1) Welcome to a new #accredited #tweetorial on parenteral #antiplatelet therapy in #neurovascular interventions. Our expert author is Fawaz Al-Mufti MD @almuftifawaz, interventional #neurologist Interventional Neurologist @NYMedcollege @WestchesterMed @neurocritical @svinsociety
2) This program is intended for #healthcare providers & is accredited for 0.5h CE/#CME for #physicians #PhysicianAssociate #nursepractitioner #nurse #pharmacists and is supported by educational grants from AstraZeneca, Bayer, and Chiesi.
3) Be sure to see prior tweetorials on #antiplatelet management, still available for credit, at cardiometabolic-ce.com/category/plate…. Faculty disclosures are listed at cardiometabolic-ce.com/disclosures/.
Read 41 tweets
Mar 22
1) Welcome to @cardiomet_CE's new series on #lipid management! This is a 10-#tweetorial program, all #accredited, that will cover it all. Our first expert author is Paul Thompson MD @PaulDThompsonMD, esteemed #cardiologist from @hartfordhosp @UConn Med & now @MGHHeartHealth ! Image
2) This #tweetorial, accredited for #CME/CE and intended for #physicians #physicianassociates #nurses #nursepractitioners #pharmacists is supported by an educational grant from Esperion Therapeutics. See faculty disclosures at cardiometabolic-ce.com/disclosures/.
3) @PaulDThompsonMD took on education re mechanisms & use of ezetimibe & bempedoic acid. He proposes a case: 45 ♂️ w/history of inferior wall #MI treated with primary angioplasty.
Read 57 tweets
Mar 1
1) Welcome to an #accredited #tweetorial on a unique emerging (in Ph3 now) option for specifically reversing the #antiplatelet effects of #ticagrelor: it's #bentracimab. Expert faculty is antithrombotic agent reversal guru @md_pollack of @UMMCnews, working to create #AHealthierMS
2) This program is intended for #healthcare professionals and is supported by an educational grant from PhaseBio Pharmaceuticals. Faculty disclosures are listed at cardiometabolic-ce.com/disclosures/, and prior programs are available for 🆓CE/#CME credit at cardiometabolic-ce.com.
3) It is an unfortunate fact of life that one cannot prescribe #anticoagulant or #antiplatelet (together, #antithrombotic) therapy without increasing a patient's #bleedingrisk. That is why it should be an individualized risk:benefit decision, ideally . . .
Read 51 tweets
Feb 8
1) Welcome to a new #accredited #tweetorial on managing #VTE at the extremes of weight & renal function. Free CE/#CME credit for following along with expert author @AryaRoopen from King’s Thrombosis Centre at King's College Hospital in London! Only the best for our learners! Image
2) When we think about "special populations" in #VTE, we think weight, age, and #cancer status. @aakonc already addressed the last of those (earn credit still at cardiometabolic-ce.com/antithrombotic…). Learn the rest here! Hello to @ProfMakris @bhwords @MiddeldorpS @fniainle @AliTaherMD
3) This educational program is intended for health care providers & is supported by a grant from Bristol Myers Squibb & its Alliance partner Pfizer, Inc. Faculty disclosures at cardiometabolic-ce.com/disclosures/. Credit for #physicians #physicianassociates #nurses #NPs #pharmacists
Read 51 tweets
Jan 25
1) Welcome to a new #accredited #tweetorial on a🗝️ topic in #cancer care & #vascular medicine: #VTE (#DVT and #PE). Cancer patients are at⬆️risk from their disease, their comorbidities, & often from their treatment. It's a sticky wicket & @cardiomet_CE is proud to welcome ...
2) ... one of the world's leading authorities on cancer-associated VTE as new faculty both here and on @onc_ce: Dr. Alok Khorana @aakonc of @ClevelandClinic, to talk about advances and best treatment in this space!
3) This educational program is intended for health care providers & is supported by a grant from Bristol Myers Squibb & its Alliance partner Pfizer, Inc. Faculty disclosures are listed at cardiometabolic-ce.com/disclosures/. Earn CE/#CME credit from prior programs at cardiometabolic-ce.com.
Read 39 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us on Twitter!

:(